Tirzepatide and menopause can fit into the same care plan when there is a medical reason to treat overweight or obesity. Menopause itself does not appear to cancel the medicine's weight effect. But tirzepatide does not replace estrogen, treat hot flashes or fix every reason weight may shift in midlife.
That distinction matters. The research is encouraging, but it is still much better at answering "can it work?" than predicting exactly what will happen for one person.
Why weight and shape can change around menopause
The scale tells only part of this story. Aging tends to bring gradual weight gain. The menopause transition can also change what that weight is made of and where fat sits.
Estrogen helps regulate how the body stores fat and uses energy. As estrogen falls, fat is more likely to collect around the abdomen, including visceral fat, the fat packed around internal organs. Muscle also becomes easier to lose. Night sweats and broken sleep can make appetite, energy and regular movement harder to manage. None of this is a failure of willpower.
A long-running U.S. study called SWAN followed women across the transition. Fat gain sped up and lean tissue began falling about two years before the final menstrual period. Across the roughly three-and-a-half-year transition, the average proportion of fat rose 3.6% while the proportion of lean tissue fell 1.9% (Greendale et al., JCI Insight 2019). Total weight kept rising more steadily, which helps explain why a waistline can change even when the scale does not move dramatically.
What the evidence says about tirzepatide and menopause
Tirzepatide works on two gut-hormone signals, GLP-1 and GIP, that help regulate appetite, fullness and blood sugar. A plain-language guide to how tirzepatide works covers that mechanism in more detail.
The original 2022 SURMOUNT-1 trial included 2,539 adults without diabetes, and about two-thirds were women. At 72 weeks, average weight reduction was 15.0%, 19.5% and 20.9% in the three tirzepatide groups, compared with 3.1% on placebo, an inactive comparison injection (Jastreboff et al., New England Journal of Medicine 2022). A later exploratory analysis across the SURMOUNT trials found reductions in both sexes and larger percentage reductions among women. Sex, though, is not the same thing as menopause status.
A 2025 post hoc analysis, meaning researchers regrouped existing trial data after the studies ended, got closer to the real question. In SURMOUNT-1, women assigned to the 15 mg trial group had average reductions of 26% before menopause, 23% during perimenopause, the transition years before periods stop, and 23% after menopause. The matching placebo figures were 2%, 3% and 3% (Tchang et al., Obesity 2025). Because the menopause groups were reconstructed rather than assigned in advance, those figures are reassuring evidence across stages, not personal forecasts.
What the hormone-therapy studies really show
Two small studies found that postmenopausal women already using menopause hormone therapy lost more weight on an incretin medicine than women who were not. Incretin medicine is the family that includes semaglutide and tirzepatide. Neither study randomly assigned hormone therapy, so neither can tell whether hormones caused the difference.
The first study looked at semaglutide. It included only 16 hormone-therapy users and 90 nonusers. At 12 months, average weight reduction was 16% versus 12% (Hurtado et al., Menopause 2024). Semaglutide is a different molecule, so that finding cannot simply be pasted onto tirzepatide. The tirzepatide and semaglutide comparison explains the practical differences.
As of September 6, 2026, the day this article was written, a Spanish Menopause Society position statement published online August 25 says direct menopause-specific evidence remains limited and care should look beyond weight to muscle, bone, nutrition and function. The evidence it reviewed includes a January 22, 2026 tirzepatide cohort of 120 postmenopausal women: 40 hormone-therapy users averaged 19.2% weight reduction versus 14.0% among 80 matched nonusers. Almost all participants were White, and the retrospective design, which looks back at existing records, still cannot prove cause and effect.
These findings are a reason for better research, not a reason to start, stop or change hormone therapy for weight loss. Hormone treatment has its own indications and risks, and that decision belongs in a separate menopause-care conversation.
Muscle and bone deserve a place in the plan
Weight loss includes both fat and lean mass, the body tissue that is not fat. That matters more after menopause because muscle and bone reserves may already be declining.
In a 160-person SURMOUNT-1 substudy using DXA, a scan that estimates fat and lean tissue, the tirzepatide group lost 21.3% of body weight on average. Fat mass fell 33.9% and lean mass fell 10.9%. Put another way, about 74% of the weight lost was fat and 26% was lean tissue (Look et al., Diabetes, Obesity and Metabolism 2025). The pattern was similar across sex and age groups, but this small substudy did not specifically answer menopause, strength or fracture questions.
A thoughtful plan therefore watches more than pounds. Food intake, protein adequacy, resistance exercise, day-to-day strength, falls, prior fractures and osteoporosis, a condition that makes bones fragile, all give the scale some needed context. Persistent nausea or eating too little can make that conversation more urgent; tirzepatide side effects explains what commonly shows up and when a provider needs to hear about it.
What a provider will ask
Menopause is one part of the intake, not an automatic yes or no. A provider will usually want to understand the timing of the last menstrual period, whether pregnancy is still possible, any current hormone therapy, sleep disruption and the pattern of weight change. Perimenopause can include unpredictable ovulation, so contraception and pregnancy plans still matter; tirzepatide and birth control covers that separate issue.
The medical screen also includes current medicines, diabetes and blood-sugar history, digestive symptoms, pancreatitis or gallbladder history, kidney problems, and any personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, a rare inherited cancer syndrome. Muscle weakness, falls, osteoporosis and previous fractures are especially relevant at this age. The prescriber sets the actual dose and pace after weighing the full picture.
Where compounded tirzepatide fits
Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA explains that compounded drugs do not receive review before marketing for safety, effectiveness or quality. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.
At Promise, a licensed provider reviews every request and prescribes only when tirzepatide is appropriate. Not everyone qualifies. If a prescription is written, a licensed U.S. compounding pharmacy prepares and dispenses the medication.